AKBA News and Press, Akebia Therapeutics Inc. From 11/08/23

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Akebia Therapeutics Inc. (AKBA) is expected to report $-0.09 for Q3 2023

2023-11-07 12:05:56 ET More on Akebia Akebia Therapeutics: Waiting For Round 2 Akebia kidney disease therapy undergoes FDA review again Akebia resubmits U.S. marketing application for kidney disease therapy Seeking Alpha’s Quant Rating on Akebia ...

2023-11-07 10:58:25 ET Major earnings expected before the bell on Wednesday include: Biogen ( BIIB ) 3D Systems ( DDD ) Roblox ( RBLX ) Teva Pharmaceutical Industries ( TEVA ) Warner Bros. Discovery ( WBD ) For further details see: Notable...

2023-11-03 17:52:59 ET Summary The NDA for Vafseo has a PDUFA action date in March 2024. Post-marketing safety data in the resubmission likely leads to an FDA nod. The company is cash poor. My initial coverage of Akebia Therapeutics, Inc. ( AKBA ), now a microcap...

Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors PR Newswire Company Strengthens Cash Position in Advance of Potential Vadadustat Launch CAMBRIDGE, Mass. , Nov. 2, 2023 /PRNewswire/ -- Akebia Th...

Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights PR Newswire Akebia to Host Conference Call on November 8 th at 8:00 a.m. ET CAMBRIDGE, Mass. , Oct. 31, 2023 /PRNewswire/ -- Akebia Therape...

2023-10-25 09:09:33 ET More on Akebia Akebia Therapeutics, Inc. (AKBA) Q2 2023 Earnings Call Transcript Akebia: 'Hold' Through Regulatory And Financial Hurdles Akebia Therapeutics: Take Profits Before Second Quarter Report Akebia resubmits U.S. marketing appl...

Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease PR Newswire March 27, 2024 Set as User Fee Goal Date CAMBRIDGE, Mass. , Oct. 25, 2023 /PRNewswire/ -- Akebia Therapeutics ...

Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023 PR Newswire CAMBRIDGE, Mass. , Oct. 18, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better t...